These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 12956518)

  • 1. Emergent patterns in the regulation of pharmaceuticals: institutions and interests in the United States, Canada, Britain, and France.
    Wiktorowicz ME
    J Health Polit Policy Law; 2003 Aug; 28(4):615-58. PubMed ID: 12956518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The big gap at the FDA.
    Stipp D
    Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
    [No Abstract]   [Full Text] [Related]  

  • 3. Harmony in drug regulation, but who's calling the tune? An examination of regulatory harmonization in health Canada.
    Lexchin J
    Int J Health Serv; 2012; 42(1):119-36. PubMed ID: 22403914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical regulation in the European Community: barriers to single market integration.
    Orzack LH; Kaitin KI; Lasagna L
    J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulators need to regulate. For health and safety issues, the nation needs watchdogs to be on guard.
    May D
    Mod Healthc; 2010 Mar; 40(9):16. PubMed ID: 20344831
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceuticals, patents, and politics: Canada and Bill C-22.
    Lexchin J
    Int J Health Serv; 1993; 23(1):147-60. PubMed ID: 8425783
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transnational pharmacogovernance: emergent patterns in the jazz of pharmaceutical policy convergence.
    Wiktorowicz M; Moscou K; Lexchin J
    Global Health; 2018 Aug; 14(1):86. PubMed ID: 30134929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Harmonization of HTA--based reimbursement and regulatory approval activities: a qualitative study.
    Tsoi B; O'Reilly D; Masucci L; Drummond M; Goeree R
    J Popul Ther Clin Pharmacol; 2015; 22(1):e78-89. PubMed ID: 25715384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Harmonising and competing for medicines regulation: how healthy are the European Union's systems of drug approval?
    Abraham J; Lewis G
    Soc Sci Med; 1999 Jun; 48(11):1655-67. PubMed ID: 10400264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug review "behind the curtain": a response to Professor Struve.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):1075-90. PubMed ID: 18618971
    [No Abstract]   [Full Text] [Related]  

  • 12. Using a drug-safety tool to prevent competition.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2014 Apr; 370(16):1476-8. PubMed ID: 24738666
    [No Abstract]   [Full Text] [Related]  

  • 13. Development of the risk-based, phased-in approach for the international harmonization of the regulation of container closure systems for drugs in Taiwan.
    Chang LC; Kang JJ; Gau CS
    Regul Toxicol Pharmacol; 2016 Jun; 77():252-6. PubMed ID: 27016398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
    Doua JY; Van Geertruyden JP
    Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The federal preemption debate in pharmaceutical labeling product liability actions.
    Gross JM; Curry JA
    Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
    [No Abstract]   [Full Text] [Related]  

  • 17. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
    Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenges of globalization in pharmaceutical law--is an international drug approval system modeled after the European system worth considering?
    Purnhagen KP
    Food Drug Law J; 2008; 63(3):623-45. PubMed ID: 19031663
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessing supplement safety--the FDA's controversial proposal.
    Cohen PA
    N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
    [No Abstract]   [Full Text] [Related]  

  • 20. The pricing of pharmaceuticals: an international comparison.
    Dickson M
    Clin Ther; 1992; 14(4):604-10; discussion 603. PubMed ID: 1525794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.